TrialHuman vaccines & immunotherapeutics2025

Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac®) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study.

Yetty Movieta Nency et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.